Vivani Medical is trading 5.6% down today at $1.47 as short-term traders lock in gains following a sharp multi-day rally.
- The recent surge was driven by the company's announced collaboration with Novo Nordisk on a long-acting semaglutide implant program.
- Shares are continuing a pullback that began on July 9, despite a lack of new negative company-specific developments.
- The downward movement appears to be a technical consolidation as the market absorbs the significant gains from the partnership news.